Skip to main content

CCTG Connection



Published:
Category: Trials
Closed to Accrual: PR21

The PR.21 study: A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease has closed to accrual as the accrual target has been met.

Read More



Published:
Category: Group updates
From the Director's Desk - 2023 A Year in Review

Looking back at 2023…

As we begin a new year, I would like to acknowledge the tremendous year of activity and highlight some achievements. These reflect the commitment and efforts of CCTG members, investigators and trial staff who develop, conduct, and report on the results from our collective research.

Read More

Published:
Category: Publications
Two new general review publications: Minding the gaps: Assessing and addressing clinical research core competencies across a network of Canadian cancer centres and Minding the gaps: Assessing and addressing clinical research core competencies across a network of Canadian cancer centres Read More

Published:
Category: Publications
Publication: Statistical publications
A threshold longitudinal Tobit quantile regression model for identification of treatment-sensitive subgroups based on interval-bounded longitudinal measurements and a continuous covariate. A composite semiparametric homogeneity test for the distributions of multigroup interval-bounded longitudinal data. Consistent covariances estimation for stratum imbalances under minimization method for covariate-adaptive randomization. Read More



Published:
Category: Group updates
2024 CCTG Annual Spring Meeting of Participants 2024
The 2024 CCTG Annual Spring Meeting of Participants will be held
Read More

Published:
Category: Group updates
A virtual roundtable on the need for EDIIA in cancer care
Please join CCTG on January 12, 2024 from 12:00-1:30 EST for a virtual round table on the need for equity, diversity, inclusivity, indigenization and accessibility (EDIIA) in cancer care and clinical trials. The goal of this roundtable is to help participants think about barriers experienced by cancer patients in Canada and how they can positively impact equity, diversity, and inclusion when working with patients and their families to improve their cancer care and clinical trial experience. Following the discussion, participants will have the opportunity to ask our panelists questions. Read More

Published:
Category: Group updates

Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:

Read More

Published:
Category: Group updates
Patient Representative Richard Wassersug
The Canadian Cancer Trials Group would like to acknowledge and send a warm thank you to Richard Wassersug for his commitment and dedication as a CCTG Patient Representative, he will be leaving the committee at the end of 2023. Richard has been a  CCTG patient representative since April 2015 and has been a member of the Genitourinary Disease Site Committee since that time.
 
Richard was diagnosed with prostate cancer over 20 years ago and has had surgery, radiation, and hormone therapy to control his disease.
Read More